A5003339658- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- BRCA gene mutations in cancer
- Multiple and Secondary Primary Cancers
- HER2/EGFR in Cancer Research
- DNA Repair Mechanisms
- Radiopharmaceutical Chemistry and Applications
- Bone Tumor Diagnosis and Treatments
- Autophagy in Disease and Therapy
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Esophageal Cancer Research and Treatment
- Oral and Maxillofacial Pathology
- Cancer Cells and Metastasis
Institut für Hämatopathologie Hamburg
2018-2023
Pathologie Hamburg-West
2018-2019
University of Graz
2014
Healthy aging depends on removal of damaged cellular material that is in part mediated by autophagy. The nutritional status cells affects both and autophagy through as-yet-elusive metabolic circuitries. Here, we show nucleocytosolic acetyl-coenzyme A (AcCoA) production a repressor during yeast. Blocking the mitochondrial route to AcCoA deletion CoA-transferase ACH1 caused cytosolic accumulation precursor acetate. This led hyperactivation AcCoA-synthetase Acs2p, triggering histone...
Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in NSCLC is compromised by a low detection rate with the established, Food Drug Administration (FDA)-approved, EpCAM-based CellSearch® System. We tested an epitope-independent method (ParsortixTM system) utilized it assess PD-L1 expression CTCs from patients. prospectively...
The worldwide approval of the combination maintenance therapy olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for routine detection driver mutations homologous recombination repair (HRR) genes genomic instability (GI), employing formalin-fixed (FFPE) paraffin-embedded tumor samples without matched normal tissue. We therefore established a DNA-based hybrid capture NGS assay an associated...
Since 2009, several first, second, and third generation EGFR tyrosine kinase inhibitors (TKI) have been approved for targeted treatment of mutated metastatic non-small lung cancer (NSCLC). A vast majority patients is improving quickly on treatment; however, resistance inevitable typically occurs after one year TKI the first second generation. Osimertinib, a TKI, has recently line in palliative setting expected to become adjuvant as well. Progression-free survival (PFS) under osimertinib...
HER2-targeted therapy is currently the subject of several studies in lung cancer and other solid tumors using either tyrosine kinase inhibitors (TKI) or targeted-antibody–drug conjugates. We describe a 61-year-old female patient with HER2 mutated adenocarcinoma lungs who received chemo-immunotherapy, followed by trastuzumab deruxtecan (T-DXd) third-line Ramucirumab/Docetaxel at disease progression. Plasma ctDNA monitoring was obtained 12 timepoints during revealed mutation allele frequencies...
In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC lacking targetable genetic alterations, immune checkpoint inhibition (ICI) become standard care in first-line treatment or beyond. PD-L1 tumor expression represents only approved predictive biomarker PD-L1/PD-1 by therapeutic antibodies. Since PD-L1-negative low-expressing tumors may also respond to ICI, additional...
Background: Recently FLAURA study demonstrated significant PFS and numeric OS benefit for Osimertinib 1st line vs. gen. TKI's Erlotinib/Gefitinib. The number of pts switching from to 3rd TKI (30%) appeared be low it is questionable whether these data represent real world sequencing treatment patterns. Therefore, we investigated the sequence pattern, i.e. percentage 2nd therapy in EGFR mt+ 3 certified lung cancer centers Germany. Methods: Data 912 1477 tested were analyzed between 2009-2017....
Immune related endonucleases have recently been described as potential therapeutic targets and predictors of response to treatment with immune checkpoint inhibitors (ICI). The aim is evaluate the association between expression 5 biomarkers involved in (CD73, CD39, VISTA, Arl4d Cytohesin-3) parallel more common ICI-predictive markers, PD-L1 Tumor Mutation Burden (TMB) ICI therapy an advanced non-small cell lung cancer (NSCLC) cohort.Patients NSCLC treated single agent were divided into...
Introduction Recently FLAURA study demonstrated significant PFS and numeric OS benefit for Osimertinib 1st line vs. gen. TKIʼs Erlotinib/Gefitinib. The number of patients switching from to 3rd TKI (30%) appeared be low it is questionable whether these data represent real world sequencing treatment patterns. Therefore, we investigated the sequence pattern, i.e. percentage 2nd therapy in EGFR mt+ pts 3 certified lung cancer centers Germany.
Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor (
EGFR TKI treatment is standard of care in pts with metastasized NSCLC carrying an activating mutation. Targeted therapies achieve a higher ORR, OS, PFS and better quality life than chemotherapy mt+ pts. With the advent 2nd 3rd generation TKI's effective 1st resistant tumors, we wanted to study impact these drugs on outcome real setting 3 lung cancer centers.
e14269 Background: Immune checkpoint inhibitors have revolutionized NSCLC treatment. At present, the only established predictive biomarker for I/O-therapy stratification are PD-L1 expression and MSI status. However, of is limited by heterogeneous even high expressors not always respond to I/O therapy. The aim study evaluate value combinations positive (Tumor Mutational Burden, PD-L1) negative (a.o. CD73 inactivating STK11 mutations) markers in patients (pts) with advanced on Methods: A...
Background: Immune checkpoint inhibitors have revolutionized NSCLC treatment. At present, the only established predictive biomarker for I/O-therapy stratification are PD-L1 expression and MSI status. However, of is limited by heterogeneous even high expressors not always respond to I/O therapy. The aim study evaluate value combinations positive (Tumor Mutational Burden, PD-L1) negative (a. o. CD73 inactivating STK11 mutations) markers in patients (pts) with advanced on
Polymorphous adenocarcinoma (PAC) is a low-grade salivary gland malignancy in contrast to variants with papillary (PAP) or cribriform (CASG) architecture and confers the second most common of minor glands. Our study aimed identify prognostic factors evaluate histomorphological molecular diagnostic criteria PACs.A series 155 PACs, including 10 PAPs 12 CASGs from population-based Cancer Registry North Rhine-Westphalia (LKR-NRW) Hamburg Salivary Gland Reference Centre (HRC) were analyzed.One...